BOOSTRIX Tdap Vaccine

We’re Collecting Info on BOOSTRIX When Taken in Pregnancy

MotherToBaby is currently enrolling pregnant people who received (or plan to receive) the BOOSTRIX Tdap vaccine in an observational study. This vaccine is recommended during the 3^rd trimester of pregnancy to prevent pertussis (whooping cough) in infants under the age of 2 months. If you have already received the Tdap vaccine during the third trimester of your pregnancy or you plan to do so, we invite you to join our observational study. Participation involves providing information about your pregnancy and your baby’s development for a certain period of time after birth.

Please note that we will not ask you to receive the Tdap vaccine as part of the study; we are solely interested in gathering data from those who have already chosen to receive BOOSTRIX during the third trimester of pregnancy. If you meet this criteria, you may be eligible to participate.

Questions?

To connect with our research team, please contact us at

Phone | 877.311.8972
Email | mothertobaby@health.ucsd.edu

We’re open Monday – Thursday from 7am – 7pm and Friday 7am – 6pm Pacific, excluding public holidays.

You can also visit our Frequently Asked Questions to learn more about participating in our studies.

How Our Studies Work

Parent-To-Be Enrolls in Study

We Gather Info about the Pregnancy

Discoveries & Insights Gained

What’s Involved?

Our BOOSTRIX study includes:
• 1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.
• Your permission to obtain a copy of your medical records from your healthcare provider for your pregnancy and for your child through 1 year of age.

All the information you provide will be kept confidential. Your privacy is important to us. We comply with strict regulations and laws set forth by state and federal agencies as well as the Institutional Review Board (IRB) at the University of California, San Diego, who oversees and monitors our research. Since we ask for your permission to obtain medical records, we will also give you detailed information on how this data will be used and how we will protect your privacy.

MotherToBaby Pregnancy Women Intro Block

What is a MotherToBaby Pregnancy Study?

MotherToBaby Pregnancy Studies is a research program seeking to understand how certain medications, vaccines, or health conditions may affect pregnancy. Our research will help people who are pregnant and/or breastfeeding and health providers make informed treatment decisions. All of our studies are observational: we will never ask someone to take or change any aspect of their current health routine.

Who Leads MotherToBaby Pregnancy Studies?

Christina Chambers, PhD, MPH is the lead investigator for MotherToBaby Pregnancy Studies, which are coordinated by UC San Diego’s Center for Better Beginnings. She is a world‐renowned perinatal epidemiologist and a Professor of Pediatrics and Family and Preventive Medicine at the UC San Diego. Her interests are in the areas of birth defects and other pregnancy outcomes, with a special focus on exposures that can cause birth defects.

“Every person deserves to know if their health conditions or the medication they need to take could affect their baby during pregnancy. We are committed to bringing you better information for healthier outcomes.”

– Christina Chambers, PhD, MPH

If you are interested in joining the study, please submit your interest below. Our research team will contact you to see if you qualify. Your information is confidential.

If you are a health professional, please fill out the Refer a Patient form and we will contact your patient to see if they qualify. Your information is confidential.

The BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine) Pregnancy Study conducted by MotherToBaby and is sponsored by GSK.

BOOSTRIX Tdap Vaccine

Help Us Better Understand the Possible Effects of Ilumya® in Pregnancy

Many people need to take medication during pregnancy to appropriately manage a chronic health condition. In some cases, avoiding or stopping medication use during pregnancy may be more harmful than taking medication. Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where you come in!

MotherToBaby is currently enrolling people who are pregnant in a study examining the use of Ilumya® (tildrakizumab-asmn) to treat psoriasis during pregnancy.

Are you currently pregnant? Did you take Ilumya® at any point in your current pregnancy? If you answered “yes” to both of these questions, then you have the opportunity to help us learn more about Ilumya® use in pregnancy.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Ilumya® & Pregnancy Study!

Join a Study

REfer A PAtient

BOOSTRIX Tdap Vaccine

Help Us Understand the Effects of Eczema in Pregnancy

Many people need to take medication during pregnancy to appropriately manage their moderate-to-severe eczema (atopic dermatitis). Yet fewer than 10% of medications have enough information to determine their safety for use in pregnancy — this is where we need you as our partner!

Do you have moderate-to-severe eczema? Are you currently pregnant? If you answered “yes” to both of these questions, you may be able to help us advance our knowledge of how moderate-to-severe eczema and its management can affect a pregnancy and a developing baby.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Eczema & Pregnancy Study!

Download the Pregnancy Study Information Sheet

Share this one-page information sheet with your patients, colleagues, or community.

Download the Eczema Pregnancy Study Information Sheet (PDF)

Eczema Pregnancy Study Flyer IRB Approved 2025

BOOSTRIX Tdap Vaccine

Help Us Better Understand the Possible Effects of Tremfya® in Pregnancy

MotherToBaby is currently enrolling people in a study examining the use of Tremfya® (guselkumab) to treat psoriasis, psoriatic arthritis, Crohn’s disease, or ulcerative colitis during pregnancy.

Are you currently pregnant? Did you take Tremfya® at any point in your current pregnancy? If you answered “yes” to both of these questions, then you have the opportunity to help us learn more about Tremfya® use in pregnancy.

Will you take the step and become our partner? Make an impact on the health of future families today by joining our Tremfya® & Pregnancy Study!

Join a Study

REfer A PAtient

BOOSTRIX Tdap Vaccine

We’re Collecting Info on Adbry® When Taken in Pregnancy

MotherToBaby is currently enrolling participants into an observational study examining the use of Adbry® (tralokinumab-ldrm) when taken during pregnancy. Our research is by observation only—we will not ask you to take or change any medications. If you join our Adbry® study, our team will simply collect some information about your pregnancy and your baby’s development for a period of time after birth.

“Help us improve the ability for pregnant people and their healthcare providers to make more informed treatment decisions by joining our Adbry® & Pregnancy Study.”

— Christina Chambers, PhD, MPH, Lead Investigator, MotherToBaby Pregnancy Studies

Our study includes:

1-3 phone interviews during your pregnancy and at least 1 interview after you have your baby.

Your permission to obtain a copy of your and your baby’s medical records from your healthcare providers.

An opportunity to receive a specialized, non-invasive exam of your baby with a study doctor.
A neurodevelopmental assessment that can also provide insight into the child’s development at approximately 4 months and 12 months of age

If you have moderate-to-severe eczema (atopic dermatitis) and have taken Adbry® (tralokinumab-ldrm) at any point in your current pregnancy or 3 months prior to pregnancy, you may qualify for this important study. Will you take the next step and help us learn more about the use of Adbry® (tralokinumab-ldrm) during pregnancy?

Join a Study

REfer A PAtient